These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19438555)

  • 1. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 2. Does adalimumab cause bullous pemphigoid?
    Toosi S; Bystryn JC
    Clin Exp Dermatol; 2010 Oct; 35(7):795. PubMed ID: 20831605
    [No Abstract]   [Full Text] [Related]  

  • 3. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy.
    Saraceno R; Citarella L; Spallone G; Chimenti S
    Clin Exp Dermatol; 2008 Mar; 33(2):154-5. PubMed ID: 18021271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urticarial vasculitis due do infliximab.
    Goulão J; Cunha H; Anes I; Bártolo E; Furtado C; Serrano P; Brandão FM
    J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):882-3. PubMed ID: 18462298
    [No Abstract]   [Full Text] [Related]  

  • 5. A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.
    Wang G; Hu X; Han S; Zhou M
    J Dermatolog Treat; 2024 Dec; 35(1):2366535. PubMed ID: 38945532
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris.
    de Groot M; de Rie MA; Bos JD
    Br J Dermatol; 2005 Oct; 153(4):843-4. PubMed ID: 16181475
    [No Abstract]   [Full Text] [Related]  

  • 7. Bullous pemphigoid during ustekinumab therapy in a psoriatic patient.
    Onsun N; Sallahoglu K; Dizman D; Su Ö; Tosuner Z
    Eur J Dermatol; 2017 Feb; 27(1):81-82. PubMed ID: 27777186
    [No Abstract]   [Full Text] [Related]  

  • 8. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 9. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis.
    Nijsten T; Spuls PI
    Br J Dermatol; 2008 Jul; 159(1):257-8. PubMed ID: 18489593
    [No Abstract]   [Full Text] [Related]  

  • 10. Efalizumab-induced bullous pemphigoid.
    Duong TA; Buffard V; André C; Ortonne N; Revuz J; Bagot M; Roujeau JC
    J Am Acad Dermatol; 2010 Jan; 62(1):161-162. PubMed ID: 20082902
    [No Abstract]   [Full Text] [Related]  

  • 11. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction?
    Monnier-Murina K; Du Thanh A; Merlet-Albran S; Guillot B; Dereure O
    Dermatology; 2009; 219(1):89-90. PubMed ID: 19270438
    [No Abstract]   [Full Text] [Related]  

  • 12. Eczematous eruption in patients with psoriasis during risankizumab treatment.
    Kromer C; Schön MP; Mössner R
    Eur J Dermatol; 2020 Oct; 30(5):599-601. PubMed ID: 33185530
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports.
    Boussemart L; Jacobelli S; Batteux F; Goulvestre C; Grange P; Carlotti A; Morini JP; Gorin I; Ziza JM; Avril MF; Dupin N
    Dermatology; 2010; 221(3):201-5. PubMed ID: 20720390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of bullous pemphigoid during secukinumab treatment for psoriasis.
    Ho PH; Tsai TF
    J Dermatol; 2017 Sep; 44(9):e220-e221. PubMed ID: 28543960
    [No Abstract]   [Full Text] [Related]  

  • 15. Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab.
    Becker JG; Mundi JP; Newlove T; Mones J; Shupack J
    J Am Acad Dermatol; 2012 Oct; 67(4):e150-1. PubMed ID: 22980274
    [No Abstract]   [Full Text] [Related]  

  • 16. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.
    Nakayama C; Fujita Y; Watanabe M; Shimizu H
    J Dermatol; 2015 Oct; 42(10):996-8. PubMed ID: 26010891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.